Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate‐Specific Membrane Antigen

Abstract

One reagent for two techniques: Compound [111In]1 provides a platform for sequential radionuclide and optical imaging of prostate cancer through targeting of the prostate-specific membrane antigen. Because the same subject can be dual-imaged after one injection of the agent, these findings support rapid clinical translation. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.